TRIM13, tripartite motif containing 13, 10206

N. diseases: 275; N. variants: 1
Disease: Cytokine Release Syndrome ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE <b>Areas covered</b>: CAR-T cell associated toxicities include cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES), alternatively known as immune effector cell-associated neurotoxicity syndrome (ICANS). 31219357 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Cytokine release syndrome (CRS) severity was the only factor after CAR-T-cell infusion associated with infection in a multivariable analysis. 29038338 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE Cytokine release syndrome (CRS) is a common and potentially fatal complication of CAR-T cell therapy. 29443792 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy, and it is critical to have a reproducible and easy method to grade CRS after CAR T cell infusions. 29499750 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects. 30072559 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. 30198955 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE Cytokine release syndrome (CRS) and CAR-T-associated encephalopathy syndrome (neurotoxicity) are the most common adverse effects associated with CAR-T therapy. 30560413 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome. 30075127 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Considering that administration of CAR T-cells has been associated with cytokine release syndrome and other potential off-tumor effects in patients, safety measures were here investigated and reported. 27907031 2016
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. 29895316 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Current research suggests that patients with a higher disease burden and higher CAR-T cell doses are positively associated with the development of ICANS, as are elevated serum levels of proinflammatory cytokines and the presence of cytokine release syndrome (CRS). 31327064 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Here we review the wide spectrum of effects associated with CAR T cell therapy with a major focus on the pathogenesis of cytokine release syndrome and neurotoxicity as the most common, potentially life-threatening effects of this treatment. 30181581 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Here, we report on the low incidence of severe cytokine release syndrome (CRS) in a subject treated with a CAR T-cell product composed of a defined ratio CD4:CD8 T-cell composition with a 4-1BB:zeta CAR targeting CD19 who also recieved early intervention treatment. 31697826 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE However, CAR T-cell therapy is associated with multiple adverse effects, including neurotoxicity and cytokine release syndrome (CRS). 30804212 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE However, CAR-T therapy-related severe cytokine release syndrome and neurological toxicity limit its clinical application in R/R DLBCL patients with high tumor burden. 31219975 2020
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE However, major concerns remain regarding toxicities, such as hypogammaglobulinemia, due to B-cell aplasia or severe cytokine release syndrome after overactivation of CAR T cells. 27329987 2016
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE In addition, cytokine release syndrome in CAR-DLI group was manageable. 30829725 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE In particular, the cytokine release syndrome is the major side-effect impeding the successful development of CAR-T in clinical trials. 26895243 2016
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE In the clinic, chimeric antigen receptor-modified T (CAR T) cell therapy is frequently associated with life-threatening cytokine-release syndrome (CRS) and neurotoxicity. 29808007 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia. 31428935 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE Management of cytokine release syndrome related to CAR-T cell therapy. 31571160 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 GeneticVariation disease BEFREE Meanwhile, CAR-T therapy-related toxicities, including cytokine release syndrome (CRS) and neurological toxicities, are drawing researchers' attention. 31055613 2019
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Moreover, we will elaborate on the main toxicities of limitations of CAR T-cell therapy, namely cytokine release syndrome and neurotoxicity. 28988742 2017
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Nonetheless, the efficacy of CD19-specific CAR-T cell therapy can be offset by significant toxicities, such as cytokine release syndrome (CRS) and neurotoxicity. 29625831 2018
CUI: C0948245
Disease: Cytokine Release Syndrome
Cytokine Release Syndrome 		0.100 Biomarker disease BEFREE Relevant challenges remain to be addressed, such as production time, early loss of CAR T cells, relapse due to loss of the target antigen, and prevention of severe cytokine release syndrome and neurotoxicity. 29171004 2018